GDI2: A Potential Drug Target and Biomarker (G2665)

Target Name: GDI2

NCBI ID: G2665

GDI2

GDI2: A Potential Drug Target and Biomarker

Guanosine diphosphate (GDP) dissociation inhibitor 2 (GDI2) is a protein that plays a critical role in cell signaling pathways. It is a potent inhibitor of GDP dissociation, which is a critical step in the intracellular signaling cascade. GDI2 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

GDI2 is a member of the G protein-coupled receptor (GPCR) family, which is a large superfamily of transmembrane proteins that play a fundamental role in cellular signaling. GPCR signaling pathways involve the formation of intracellular signaling c cascades, which involve the interactions between various protein components. GDI2 is a critical component of these signaling pathways, as it inhibits the dissociation of GPCRs from its downstream signaling components.

GDI2 is expressed in most tissues and cells and has been shown to play a role in various physiological processes, including cell signaling, cell division, and tissue repair. GDI2 has also been shown to be involved in several diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

One of the key challenges in studying GDI2 is its high sensitivity to inhibitors. This is because GDI2 is a potent inhibitor of its own, and many small molecules that are used to study its function have a high affinity for GDI2. This makes it difficult to study GDI2's effects in a controlled manner. However, researchers have been able to overcome this challenge by using high-throughput assays, such as yeast two-hybrid assays, to study the effects of GDI2 on its own activity.

In addition to its potential drug-related applications, GDI2 has also been shown to be a potential biomarker for several diseases. For example, GDI2 has been shown to be downregulated in various neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease. This suggests that GDI2 may be a useful biomarker for these disorders. Additionally, GDI2 has also been shown to be downregulated in cancer cells, which may make it an attractive target for cancer therapies.

Another promising aspect of GDI2 is its potential role in targeting G protein-coupled receptors (GPCRs) that are involved in diseases such as diabetes, hypertension, and cardiovascular diseases. GDI2 has been shown to inhibit the activity of several GPCRs, including the well-known insulin receptor, which is involved in regulating blood sugar levels. This suggests that GDI2 may be a useful target for therapies that target these diseases.

In conclusion, GDI2 is a protein that plays a critical role in cell signaling pathways. Its high sensitivity to inhibitors and its role in the regulation of various physiological processes make it an attractive target for drug development. Additionally, GDI2 has also been shown to be a potential biomarker for several diseases, including cancer and neurodegenerative disorders. Further research is needed to fully understand the role of GDI2 in these diseases and to develop effective therapies that target it.

Protein Name: GDP Dissociation Inhibitor 2

Functions: GDP-dissociation inhibitor preventing the GDP to GTP exchange of most Rab proteins. By keeping these small GTPases in their inactive GDP-bound form regulates intracellular membrane trafficking (PubMed:25860027). Negatively regulates protein transport to the cilium and ciliogenesis through the inhibition of RAB8A (PubMed:25860027)

The "GDI2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GDI2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets